Pharmacology

Original paper

Anti-inflammatory effect of tranexamic acid against trauma-hemorrhagic shock-induced acute lung injury in rats

THE ROLE OF TXA IN RATS WITH T/HS-INDUCED ALI

Yue TENG1, 2)#, Cong FENG1)#, Yunen LIU2-4), Hongxu JIN2), Yan GAO2)*, and Tanshi LI1)*

Author affiliations: 1)Department of Emergency Medicine, Chinese PLA General Hospital, Beijing 100853, People’s Republic of China. 2)Department of Emergency Medicine, General Hospital of Shenyang Military Area Command, Shenyang 110016, People’s Republic of China. 3)Laboratory of Rescue Center for Severe Wound and Trauma PLA, Shenyang 110016, People’s Republic of China. 4)Liaoning Key Laboratory of Severe Wound and Trauma and Organ Protection, Shenyang 110016, People’s Republic of China.

*Corresponding authors: Dr. Tanshi Li, Department of Emergency Medicine, Chinese PLA General Hospital, 28 Fuxing Road, Beijing 100853, People’s Republic of China, and Dr. Yan Gao, Department of Emergency Medicine, General Hospital of Shenyang Military Area Command, 83 Wenhua Road, Shenyang 110016, People’s Republic of China. Tel: +86-10-66936224.

#Yue Teng and Cong Feng contributed equally to this study.
Abstract
It has been demonstrated that tranexamic acid (TXA), a synthetic derivative of lysine, alleviates lung damage in a trauma-hemorrhagic shock (T/HS) model. Nevertheless, the mechanism of TXA against acute lung injury (ALI) has not deeply elaborated. In this study, we generated a T/HS rat model based on previous research, and TXA (50 mg/kg and 100 mg/kg) was intravenously injected into these rats prior to or post T/HS. The results revealed that the decreased survival rate and impaired lung permeability of the rats caused by T/HS were improved by TXA pretreatment or posttreatment. T/HS-triggered over-generation of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in bronchoalveolar fluid and serum was inhibited by TXA, and the enzymatic activity of myeloperoxidase (MPO) in lung tissues was suppressed by TXA as well. Furthermore, TXA treatment deactivated the poly ADP-ribose polymerase-1 (PARP1)/nuclear factor κB (NF-κB) signaling pathway in the lungs of T/HS rats, as evidenced by increased IκBα expression, and decreased cleaved PARP1, p-p65 (Ser276), p-p65 (Ser529), p-IκBα (ser32/ser36), and intercellular adhesion molecule-1. While the expression level of total p65 did not change after T/HS, its DNA binding activity was strengthened. Both TXA pretreatment and posttreatment suppressed this effect on the DNA binding activity of NF-κB. Taken together, our results reveal that administration of TXA effectively relieves T/HS-induced ALI, at least in part, by attenuating the abnormal pulmonary inflammation.

Key words: acute lung injury, hemorrhagic shock, inflammation, NF-κB, tranexamic acid

Introduction
Hemorrhagic shock caused by trauma (T/HS) is associated with a high mortality rate [7]. Serious T/HS can lead to ischemia-reperfusion injury of multiple organs with a systemic inflammatory response [3, 30]. Acute lung injury (ALI) is one of the main complications of T/HS, and it can deteriorate into acute respiratory distress syndrome (ARDS) [1]. Previous studies have demonstrated that intestinal ischemia induced by massive bleeding causes damage to the gastrointestinal mucous membrane barrier, evoking enterogenous bacteremia and endotoxemia, eventually leading to ALI [5, 11]. Hence, development of new drugs against inflammation may contribute to the treatment of T/HS with ALI.

Tranexamic acid (TXA) is a synthetic derivative of lysine that can suppress fibrinolysis and reduce blood loss by blocking the lysine-binding sites of plasminogen and plasmin [25]. Currently, TXA is widely used in blood disorders induced by various types of trauma, and its oral administration can decrease blood loss-induced mortality [14]. Peng et al. revealed that an enema of TXA relieved lung damage through activation of syndecan-1 in rats with hemorrhagic shock [24]. Moreover, TXA has been demonstrated to exert anti-inflammatory effects in multiple diseases [4, 6, 15]. Based on previous research, we speculate that TXA alleviates T/HS-associated ALI by attenuating pulmonary inflammation.

In the present study, to verify our hypothesis, rats were intravenously injected with TXA (50 mg/kg and 100 mg/kg) prior to or after T/HS. Then, the survival rate, lung permeability, and levels of inflammation-related factors in bronchoalveolar lavage fluid (BALF), serum, or lung tissues of these rats were evaluated. Furthermore, we explored the underlying molecular mechanisms of TXA against inflammation in rats with T/HS-triggered ALI.
Materials and methods

Animals and grouping

Male Sprague Dawley rats weighing about 280 ± 20 g (10 weeks old) were purchased from Beijing HFK Bioscience Co., Ltd (Beijing, China; Certificate No. SCXK (Jing) 2014-0004). The rats were housed in a light- and temperature-controlled room and allowed to eat and drink freely. This study was approved by the General Hospital of Shenyang Military Area Command and conducted according to the National Research Council's Guide for the Care and Use of Laboratory Animals.

All rats were randomly assigned to six groups (labeled as a, b, c, d, e, and f), and each group contained 28 rats: a, sham; b, T/HS group; c, pretreatment with TXA (50 mg/kg) + T/HS group; d, pretreatment with TXA (100 mg/kg) + T/HS group; e, T/HS + posttreatment with TXA (50 mg/kg) group; f, T/HS + posttreatment with TXA group (100 mg/kg). TXA was purchased from Aladdin Chemistry Co. Ltd. (Shanghai, China) and dissolved in sterile saline solution.

Model of T/HS and treatment

The model of T/HS was established by referring to previous studies [15, 31]. Briefly, the rats were anaesthetized by an intraperitoneal injection of pentobarbital sodium (50 mg/kg body weight) and fixed on an operating table. Then, a 0.5-cm incision was made in the inguinal region, and both femoral arteries and the right jugular vein were exposed. The right femoral artery was linked to a blood pressure monitoring system (BL-420S, Taimeng Science Technology, Ltd., Chengdu, China) with a heparinized catheter. Blood was collected from the left femoral artery via a catheter. The right jugular vein was used for liquid administration. The rectal temperature was
maintained at 37°C throughout the experiment. Afterwards, hemorrhagic shock was generated via withdrawal of blood and maintenance of the blood pressure at 30 mmHg for 90 min. Rats were intravenously injected with TXA prior to surgery in groups c and d and after surgery in groups e and f.

After the above procedures, the rats were fed under the same conditions. Four hours later, 18 rats were randomly selected from each group: 6 rats were used for evaluation of lung permeability with Evans blue dye, and the other 12 (to obtain sufficient samples, each experimental group contained 6 rats) were used for collection of orbital blood, BALF, serum, and lung tissue samples. The remaining 10 rats in each group were used for survival analysis.

**Hematoxylin-eosin (HE) staining**

Tissue samples were routinely processed as paraffin-embedded sections and cut to a thickness of 5 µm. The sections were dewaxed in xylene and hydrated in ethanol-water mixtures. Thereafter, they were soaked in hematoxylin solution for 5 min, in hydrochloric acid-alcohol solution for 3 seconds, and then in eosin for 5 min. The sections were examined with a microscope (DP73, Olympus Corporation, Tokyo, Japan) following dehydration and sealing.

**Evans blue dye (EBD)**

Lung permeability was evaluated by EBD as described previously [27]. Briefly, rats in different groups were injected with 1 ml of 1% EBD solution via the jugular vein. After 5 min, a blood sample (1.5 ml) was collected from the femoral artery catheter. Twenty minutes later, the rats were sacrificed, and the BALF was collected by rinsing the excised lungs with 5 ml of normal saline 3 times; the supernatant was gathered by
centrifugation. The concentration of EBD in plasma and BALF was determined by
detecting the absorbance value at 620 nm with a microplate reader (Elx800, BioTek,
Winooski, VT, USA). The ratio of EBD in the BALF to that in the plasma was
calculated.

**Lung permeability index**

Lung permeability index was calculated as the ratio of the BALF protein
concentration to the serum protein concentration as described previously [20]. In brief,
a portion (1 μl) of sample supernatants was mixed with 4 μl normal saline and 250 μl
Coomassie brilliant blue G250. A microplate reader (BioTek) was used to measure
the absorbance at 595 nm. The protein concentration of BALF and plasma was
computed based on the standard curve of bovine serum albumin (BSA).

**Enzyme-linked immunosorbent assay (ELISA) and myeloperoxidase (MPO)
activity**

The content of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in BALF and
serum was detected with commercially available ELISA kits (Biotech Co., Ltd.,
Hangzhou, China) according to the manufacturer's protocols. The activity of MPO in
lung tissues was measured using a commercial kit (Nanjing Jiancheng Bioengineering
Institute, Nanjing, China) according to the manufacturer's instructions.

**Western blot**

The total protein was isolated from tissue samples using RIPA lysis buffer (Beyotime,
Shanghai, China) containing the protease inhibitor PMSF. The protein concentration
was determined using a BCA protein assay kit (Beyotime). Then, SDS-PAGE was
carried out to separate protein fractions. The proteins were transferred to PVDF
membranes (EMD Millipore, Bedford, MA, USA), and the membranes were blocked
with 5% skim milk and incubated with cleaved poly ADP-ribose polymerase-1
(PARP1) (CST, Danvers, MA, USA), p-p65 Ser276 (Bioss, Beijing, China), p-p65
Ser529 (Abcam, Cambridge, Great Britain), p65 (Bioss), p-IκBα Ser32/Ser36 (Bioss),
IκBα (Bioss), intercellular adhesion molecule-1 (ICAM-1) (Proteintech, Wuhan,
China), and β-actin (Bioss) antibodies overnight at 4°C. Thereafter, the primary
antibodies were coupled with horseradish peroxidase-labeled goat anti-mouse or goat
anti-rabbit second antibodies for 2 h at room temperature. Proteins were visualized by
enhanced chemiluminescence (Beyotime) with a gel imaging system (Beijing Liuyi
Instrument Factory, Beijing, China).

Electrophoretic mobility shift assay (EMSA)

An EMSA kit (Viagene Biotech, Inc., Tampa, FL, USA) was employed to examine
active p65 according to the manufacturer's protocol. Briefly, the nuclear protein was
extracted from tissue samples using a nuclear and cytoplasmic protein extraction kit
(Beyotime), and the protein concentration was determined with a BCA protein assay
kit (Beyotime). Five microliters of diluted protein (5 μg/μl) was mixed with 0.5 μl
biotin-labeled NF-κB probe, 8 μl double-distilled water, and 1.5 μl reaction fluid
(10x). The reaction mixtures were electrophoresed on non-denaturing polyacrylamide
gel. Then the protein-DNA complexes were transferred onto a membrane and cross-
linked under an ultraviolet lamp for 30 min. After incubation with HRP-conjugated
streptavidin, the specific bands were visualized by enhanced chemiluminescence.

Immunohistochemical analysis

The expression levels of inducible nitric oxide synthase (iNOS), monocyte
chemoattractant protein-1 (MCP-1), cyclooxygenase 2 (COX-2), and vascular cell
adhesion molecule-1 (VCAM-1) were determined by immunohistochemical analysis.

In brief, paraffin-embedded sections were subjected to antigen retrieval with citrate buffer following dewaxing and dehydration. Endogenous peroxidase activity was eliminated by incubation in 3% H₂O₂. Then, the sections were sealed with goat serum and incubated with primary antibodies against iNOS (Proteintech), MCP-1 (abcam), COX-2 (Boster, Wuhan, China), and VCAM-1 (Proteintech) overnight at 4°C. The primary antibodies were probed with biotin-labeled goat anti-rabbit IgG. After incubation with horseradish peroxidase, counterstaining with hematoxylin, and coloration with DAB, the sections were observed with a microscope (Olympus).

**Statistical analysis**

Each experiment was repeated three times except the survival analysis. The data were expressed as the mean ± standard deviation (SD). Significant differences were analyzed by one-way analysis of variance followed by Tukey's multiple comparison test via the GraphPad Prism 7.0 software (GraphPad Software, La Jolla, CA, USA). A P less than 0.05 was considered to indicate statistical significance.

**Results**

**Administration of TXA raised the survival rate of T/HS rats**

We first studied the effect of TXA on survival of T/HS rats. As shown in Figure 1, the survival rate of T/HS rats decreased by 50% at 24 h as compared with that of sham-operated rats. While pretreatment with 50 and 100 mg/kg TXA increased the survival rate of T/HS rats by 10% and 30%, respectively, posttreatment with 100 mg/kg TXA
increased it by 30%. These data suggested a survival-promoting effect of TXA in T/HS rats.

**Administration of TXA alleviated ALI in T/HS rats**

We subsequently investigated the effects of TXA on T/HS-associated ALI. The results of HE staining showed that the lung tissues of T/HS rats were more compact than those of sham-operated rats and that TXA pretreatment (50 mg/kg and 100 mg/kg) or posttreatment (100 mg/kg) could alleviate such morphological changes (Figure 2A). Moreover, lung permeability to EBD and the lung permeability index were assessed. As shown in Figure 2B and C, these two indicators were significantly increased after T/HS but were decreased by TXA treatments.

**Administration of TXA suppressed pulmonary inflammation of T/HS rats**

Next, we determined whether TXA had anti-inflammatory effects. As shown in Figure 3A and B, the levels of IL-6 and TNF-α in BALF and serum of T/HS rats were upregulated as compared with those of sham-operated rats. The elevation of these pro-inflammatory cytokines was suppressed by TXA pretreatment (50 mg/kg and 100 mg/kg) or posttreatment (100 mg/kg). In addition, the enhanced enzymatic activity of MPO in lung tissues of T/HS rats was attenuated by TXA treatment (Figure 3C).

**Administration of TXA deactivated the PARP1/NF-κB signaling pathway**

Finally, we explored the molecular mechanism of the anti-inflammation effects of TXA. As shown in Figure 4A, western blot analysis showed that the increased levels of cleaved PARP1, p-p65 (Ser276), p-p65 (Ser529), p-IκBα (ser32/ser36), and ICAM-1 the decreased level of IκBα in lung tissues caused by T/HS were inhibited by TXA pretreatment (50 mg/kg and 100 mg/kg) or posttreatment (100 mg/kg). While the
expression of total p65 did not change in all groups (Figure 4A), the DNA binding activity of NF-κB was enhanced in T/HS lungs and suppressed by TXA treatment (Figure 4B). Moreover, the expression levels of iNOS, MCP-1, COX-2, and VCAM-1 in lung tissues of T/HS rats were upregulated, and these changes were inhibited as a result of TXA administration (Figure 4C).

**Discussion**

Bleeding can be triggered by unexpected accidental trauma, but some bleeding is an expected consequence of special situations, such as cardiac surgery [19]. Thus, in this study TXA was given to some rats prior to T/HS to determine whether it could prevent bleeding-induced ALI. Our results showed that TXA pretreatments of 50 or 100 mg/kg improved the survival rate, inhibited pulmonary inflammation, and deactivated the PARP1/NF-κB pathway in T/HS rats. As for the posttreatment, only the higher dose of TXA showed survival-promoting and lung-protective effects. These data suggested that giving TXA to patients prior to T/HS assault was a better choice.

The molecular mechanism of ALI after T/HS is very complicated. It has been demonstrated that the intestinal mucosal barrier was destroyed after T/HS. Subsequently, the bacteria spread to the bloodstream, leading to systemic inflammatory response syndrome (SIRS) [8, 23]. During the development of SIRS, many pro-inflammatory cytokines are released excessively, including TNF-α and IL-6 [28]. The activity of MPO, an enzyme secreted by various inflammatory cells, was upregulated during the inflammatory response [32]. Our data here illustrated that TXA could inhibit over-generation of TNF-α and IL-6 in BALF and serum and
suppress MPO activity in the lung tissues of T/HS rats, indicating that TXA exerted anti-inflammatory effects in experimental ALI.

Multiple pathways are involved in the inflammatory response, such as mitogen-activated protein kinase (MAPK) [17], phosphoinositide 3-kinase (PI3K) [12], Akt [29], and mammalian target of rapamycin (mTOR) [9]. Moreover, several previous studies have demonstrated that aberrant activation of pro-inflammatory toll-like receptor-4 (TLR4) [26], high-mobility group box 1 (HMGB1) [16], and NF-kB [21] pathways is linked to T/HS-associated ALI. NF-κB is a family that contains five members: NF-κB1 (p105/p50), NF-κB2 (p100/p52), RelA (p65), RelB, and c-Rel. These members constitute various active NF-κB heterodimers that bind to specific DNA sequences of their target genes at the promoter region. NF-κB can be activated by multiple stress stimuli (such as TNF-α and IL-6) via degradation of IκB proteins. The activated NF-κB rapidly translocates to the nucleus, where it initiates the expression of its downstream targets and proinflammatory cytokines [2, 10, 13]. In turn, the pro-inflammatory cytokines, including TNF-α and IL-6, activate the NF-κB pathway, amplifying the inflammatory response [22]. Our study demonstrated that TXA could inhibit T/HS-induced activation of the NF-κB pathway in rat lungs, as evidenced by the increased IκBα expression and decreased p-p65 (Ser276), p-p65 (Ser529), p-IκBα (ser32/ser36), and active p65 expression. The amount of total p65 did not change post T/HS, but the DNA binding activity of NF-κB was enhanced, suggesting that T/HS could induce the release of p65 from its inhibitor IκBα [18]. The activated NF-κB signaling in the rat lung was inhibited by TXA. The elevation of NF-κB downstream target genes ICAM-1, iNOS, MCP-1, COX-2, and VCAM-1 in T/HS rats was also suppressed by TXA. In addition, the cleaved level of PARP1, a factor known to promote NF-kB nuclear retention [33], was decreased by TXA as well.
Taken together, our results demonstrate that the survival-promoting effects of TXA given prior to or post T/HS are associated with its anti-inflammatory action in the lung. TXA can attenuate the over-activation of the pro-inflammatory PARP1/NF-κB pathway as well.

**Acknowledgments**

This study was supported by grants from the Welfare Industry Research Program of the Ministry of Health (No. 201502019), the National Natural Science Foundation of China (Nos. 81371561 and 81701961), the PLA General Hospital Science and Technology Project (Nos. 16KMM56 and 2017FC-WJFWZX-30), and the PLA Logistic Major Science and Technology Project (Nos. 14CXZ005, AWS15J004, BWS14J041, and 16QNP135). The authors are grateful to High-tech Zone Laboratory of Public Test and Analysis Service (Shenyang, China) for English editing.

**Conflict of interest**

The authors declare that they have no conflicts of interest.
References


    Zhou, J., Yuan, Z., and Wu, Y. 2015. The activation of mTOR is required for
    monocyte pro-inflammatory response in patients with coronary artery disease.
    Biochim Biophys Acta. 1851: 882-897.
    inflammation and cancer. Mol Cancer. 12: 86.
    2013. Oral versus intravenous tranexamic acid in enhanced-recovery primary
    total hip and knee replacement: results of 3000 procedures. Bone Joint J. 95-B:
    1556-1561.
    Tranexamic acid attenuates inflammatory response in cardiopulmonary bypass
    surgery through blockade of fibrinolysis: a case control study followed by a
16. Kim, J.Y., Park, J.S., Strassheim, D., Douglas, I., Diaz del Valle, F., Asehnoune,
    K., Mitra, S., Kwak, S.H., Yamada, S., Maruyama, I., Ishizaka, A., and
    Abraham, E. 2005. HMGB1 contributes to the development of acute lung


Figure legends

Figure 1. Treatment with TXA increased the survival rate of rats with T/HS. The survival of rats following different experimental manipulations was evaluated. a, Sham; b, T/HS group; c, pretreatment with TXA (50 mg/kg) + T/HS group; d, pretreatment with TXA (100 mg/kg) + T/HS group; e, T/HS + posttreatment with TXA (50 mg/kg) group; f, T/HS + posttreatment with TXA group (100 mg/kg).

Figure 2. Treatment with TXA relieved ALI of rats caused by T/HS. (A) Lung histological changes were examined by HE staining. (B) The ratio of the percentage of EBD in the BALF to EBD in the plasma. (C) Lung permeability index: BALF protein concentration /plasma protein concentration. a, Sham; b, T/HS group; c, pretreatment with TXA (50 mg/kg) + T/HS group; d, pretreatment with TXA (100 mg/kg) + T/HS group; e, T/HS + posttreatment with TXA (50 mg/kg) group; f, T/HS + posttreatment with TXA group (100 mg/kg). Data are presented as the mean ± SD. *P<0.05; ** P<0.01; ***P<0.001.

Figure 3. Treatment with TXA inhibited inflammation of the lung in rats with T/HS. The levels of IL-6 and TNF-α in (A) BALF and (B) serum were detected. (C) MPO activity in lung tissue was evaluated. a, Sham; b, T/HS group; c, pretreatment with TXA (50 mg/kg) + T/HS group; d, pretreatment with TXA (100 mg/kg) + T/HS group; e, T/HS + posttreatment with TXA (50 mg/kg) group; f, T/HS + posttreatment with TXA group (100 mg/kg). Data are presented as the mean ± SD. *P<0.05; ** P<0.01; ***P<0.001.
Figure 4. Treatment with TXA attenuated the PARP1/NF-κB signaling pathway. (A) The expression levels of cleaved PARP1, p65, p-p65 Ser276, p-p65 Ser529, IκBα, p-IκBα, and ICAM-1 were detected by western blotting. The bands semiquantitatively evaluated by densitometry, and the data were normalized to those of the internal control, β-actin. (B) Active p65 was examined through EMSA. The band (active p65) was semiquantitatively evaluated by densitometry. (C) The content of iNOS, MCP-1, COX-2, and VCAM-1 was determined by immunohistochemical analysis. The mean density of staining was calculated as the integrated optical density (IOD) sum/area. a, Sham; b, T/HS group; c, pretreatment with TXA (50 mg/kg) + T/HS group; d, pretreatment with TXA (100 mg/kg) + T/HS group; e, T/HS + posttreatment with TXA (50 mg/kg) group; f, T/HS + posttreatment with TXA group (100 mg/kg). Data are presented as the mean ± SD. *P<0.05; ** P <0.01; ***P<0.001.
Figure 1. Treatment with TXA increased the survival rate of rats with T/HS.
Figure 2. Treatment with TXA relieved ALI of rats caused by T/HS.
Figure 3. Treatment with TXA inhibited inflammation of the lung in rats with T/HS.
Figure 4. Treatment with TXA attenuated the PARP1/NF-κB signaling pathway.